

SOPHiA DDM™ Trial Match

Accelerate clinical trial enrollment

Leverage real-world data to change the way you design clinical trials. Improve site selection, identify the right biomarkers and patient populations, and shorten enrollment cycles with **on-demand access** to the SOPHiA DDM™ Platform and its wealth of clinical data from across the globe.

86%

of trials fail to reach enrollment targets on time¹



Patient Identification

Automate the real-time identification of biomarker-positive patients

Site Selection

Identify sites with **large cohorts** of biomarker-positive patients

Trial Rescue

Find **additional sites** for ongoing trials not meeting enrollment goals



Benefits of SOPHiA DDM™ Trial Match



Empower your decision-making process by tapping into structured **on-demand clinical data**




Save precious time by reviewing and assessing key site and patient data on a **single platform**



Accelerate enrollment by exploring real-time data from a vast **clinical research network** spread across 750+ institutions

1. Treweek, S., et al. 2013. BMJ Open. 3:e002360. doi: 10.1136/bmjopen-2012-002360

Design Biomarker-Driven Trials with SOPHiA DDM™ Trial Match



CASE STUDY

SOPHiA DDM™ Trial Match Allows the Timely Detection of *EGFR* ex19del

EGFR-activating mutations leading to deletions in exon 19 (ex19del) are highly prevalent among NSCLC patients and a major predictor of the response to TKI therapies. The early detection of these alterations by NGS testing could improve prognosis significantly.²

Key outcomes

- 1 SOPHiA DDM™ Trial Match was activated on 2 sites
- 2 An alert was set to detect patients with *EGFR* ex19del
- 3 In only 4 months, the solution identified **43 positive patients**
- 4 Amongst the geographical regions within the scope of the trial, SOPHiA GENETICS had a footprint in 9 countries (36 institutions)



2. Yun Lee J. et al. 2016. *Oncotarget*. 7(6):6984-6993. doi: 10.18632/oncotarget.6874

About SOPHiA GENETICS

750+

Healthcare Institutions

70+

Countries


1 Million+

Genomic Profiles

SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ platform and related solutions, products and services were used by more than 750 hospitals, laboratories, and biopharma institutions globally in 2021.

The information included in this flyer has been prepared for and is intended for viewing by a global audience. This flyer contains information about products which may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please consult local sales representatives. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. SOPHiA DDM™ Trial Match is for Research Use Only and is not intended for purposes other than research. SOPHiA DDM™ is not for diagnostic, therapeutic, or treatment purposes.

Want to learn more?



Or contact us at:
info@sophigenetics.com